Community
Anand Reddi is a global health specialist at Gilead Sciences, Inc., a major multinational biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines.
At Gilead, Reddi focuses on catalyzing HIV and viral hepatitis health systems strengthening initiatives as well as innovative health financing for resource limited settings in Africa and Asia. Prior to Gilead, Reddi was a Fulbright Scholar in South Africa. His Fulbright research demonstrated the benefits of decentralized models of care on antiretroviral treatment outcomes despite the challenges of a healthcare limited setting. Reddi has also been active in U.S. global health policy issues. In the summer of 2010, his writings and advocacy directly challenged the Obama administration’s flat lining of global HIV treatment funds resulting in the restoration of $366 million for HIV treatment in Uganda. Reddi is a graduate of the University of Michigan, Ann Arbor and he studied medicine at the University of Colorado, School of Medicine.
